Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term.

Objective: To determine if 6 months of neo-adjuvant androgen deprivation is associated with the long-term risk of cardiac mortality. Methods: In the TROG 96.01 tr